Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate.

Mahler, Donald A; Ohar, Jill A; Barnes, Chris N; Moran, Edmund J; Pendyala, Srikanth; Crater, Glenn D

Mahler, Donald A; Ohar, Jill A; Barnes, Chris N; Moran, Edmund J; Pendyala, Srikanth; Crater, Glenn D.

Afiliación

Mahler DA; Geisel School of Medicine at Dartmouth, Hanover, New Hampshire and Respiratory Services, Valley Regional Hospital, Claremont, New Hampshire.
Ohar JA; Wake Forest University Medical Center, Winston-Salem, North Carolina.
Barnes CN; Theravance Biopharma US, Inc., South San Francisco, California.
Moran EJ; Theravance Biopharma US, Inc., South San Francisco, California.
Pendyala S; Theravance Biopharma US, Inc., South San Francisco, California.
Crater GD; Theravance Biopharma US, Inc., South San Francisco, California.

Chronic Obstr Pulm Dis ; 6(4)2019 Oct 23.

Article en En | MEDLINE | ID: mdl-31647854

Palabras clave

dry powder inhalers; long-acting muscarinic antagonist; nebulizers; peak inspiratory flow rate; tiotropium

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Chronic Obstr Pulm Dis Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google